QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 9.201

Change

+0.03 (+0.28)%

Market Cap

N/A

Volume

341.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.06 (-0.11%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

+7.42 (+1.34%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.03 (-0.19%)

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

+1.48 (+1.51%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 46.87B
0ZC:F Zscaler Inc

+6.85 (+2.71%)

USD 37.92B
BSND:F Danone SA

+0.10 (+0.68%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

+1.10 (+0.87%)

USD 24.77B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.75% 11% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.75% 12% F 31% F
Trailing 12 Months  
Capital Gain -10.29% 13% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.29% 12% F 34% F
Trailing 5 Years  
Capital Gain 35.33% 43% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.33% 44% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 11.48% 77% C+ 69% C-
Dividend Return 11.48% 75% C 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.54% 57% F 88% B+
Risk Adjusted Return 99.45% 91% A- 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike